Etofenamate

Identification

Name
Etofenamate
Accession Number
DB08984
Description

Etofenamate is used to treat muscle and joint paint. It is a non-steroidal anti-inflammatory drug (NSAID).

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 369.335
Monoisotopic: 369.118792684
Chemical Formula
C18H18F3NO4
Synonyms
  • Etofenamate
  • Etofenamato
  • Etofenamatum
External IDs
  • BAY D 1107
  • BAY-D-1107
  • TVX 485
  • TVX-485
  • TVX485
  • WHR-5020

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirEtofenamate may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Abciximab.
AcarboseEtofenamate may decrease the excretion rate of Acarbose which could result in a higher serum level.
AcebutololEtofenamate may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Etofenamate.
AcemetacinThe risk or severity of adverse effects can be increased when Etofenamate is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Etofenamate.
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Etofenamate.
Acetylsalicylic acidThe risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Acetylsalicylic acid.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
International/Other Brands
Activon (Meda) / Aspitopic (Bayer) / Bayagel (Bayer) / Bayro (Bayer) / Etobay (Bayer) / Gemadol (Meda) / Glasel (Meda) / Rheumon (Bayer) / Ticatrop (Meda)

Categories

ATC Codes
M02AA06 — Etofenamate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Trifluoromethylbenzenes / Aminobenzoic acids and derivatives / Aniline and substituted anilines / Benzoyl derivatives / Vinylogous amides / Amino acids and derivatives / Carboxylic acid esters / Secondary amines / Dialkyl ethers / Monocarboxylic acids and derivatives
show 6 more
Substituents
Alcohol / Alkyl fluoride / Alkyl halide / Amine / Amino acid or derivatives / Aminobenzoic acid or derivatives / Aniline or substituted anilines / Aromatic homomonocyclic compound / Benzoate ester / Benzoyl
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
KZF0XM66JC
CAS number
30544-47-9
InChI Key
XILVEPYQJIOVNB-UHFFFAOYSA-N
InChI
InChI=1S/C18H18F3NO4/c19-18(20,21)13-4-3-5-14(12-13)22-16-7-2-1-6-15(16)17(24)26-11-10-25-9-8-23/h1-7,12,22-23H,8-11H2
IUPAC Name
2-(2-hydroxyethoxy)ethyl 2-{[3-(trifluoromethyl)phenyl]amino}benzoate
SMILES
OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(=C1)C(F)(F)F

References

Synthesis Reference

U.S. Patent 3,692,818.

General References
Not Available
KEGG Drug
D04102
PubChem Compound
35375
PubChem Substance
310264945
ChemSpider
32560
RxNav
24608
ChEBI
94731
ChEMBL
CHEMBL1451633
ZINC
ZINC000002034516
Drugs.com
Drugs.com Drug Page
Wikipedia
Etofenamate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedDiagnosticDermatitis, Photocontact1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SprayTopical10 %
SolutionIntramuscular1 g/2ml
Injection, solutionIntramuscular1 g/2ml
InjectionIntramuscular1 gr/2ml
SprayTopical100 mg/ml
InjectionIntramuscular1 g
GelTopical40 g
PlasterTopical70 mg
CreamTopical100 mg/g
CreamTopical50 mg/g
Injection, solutionIntramuscular1 g
GelTopical50 mg/g
InjectionIntramuscular1000 mg/2ml
InjectionIntramuscular1 g/2ml
CreamTopical10 mg/g
CreamTopical10 mg
CreamTopical10 %
CreamTopical50 gr
SolutionIntramuscular1 g
SprayOral100 mg/mL
GelTopical100 mg/g
GelTopical10 %
GelTopical5 %
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00936 mg/mLALOGPS
logP3.53ALOGPS
logP4.86ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.79 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity89.88 m3·mol-1ChemAxon
Polarizability35.57 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Major thyroid hormone transport protein in serum.
Gene Name
SERPINA7
Uniprot ID
P05543
Uniprot Name
Thyroxine-binding globulin
Molecular Weight
46324.12 Da
References
  1. CYTOMEL (liothyronine) FDA label [File]

Drug created on June 10, 2014 11:10 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates